The strong responder data de-risks the CRSwNP program and supports the quarterly dosing advantage over competitors like Tezspire (monthly). Watch for Phase 3 initiation in Q1 2027 and potential partnership or financing needs given the capital-intensive path to approval. The stock may re-rate on pipeline confidence, but near-term volatility remains high with no revenue and binary Phase 3 risk ahead.
Price Chart
Executive Summary
Upstream Bio presented positive responder analyses from the Phase 2 VIBRANT trial of verekitug in CRSwNP at EAACI 2026, showing 79% of treated participants achieved clinically meaningful nasal polyp score improvements vs 24% for placebo (OR 12.06, p<0.0001). The data supports quarterly dosing and the company plans to initiate Phase 3 trials in CRSwNP and severe asthma in Q1 2027. This is a clinical-stage biotech with no approved products or revenue, so the read is bullish on pipeline momentum but tempered by the early stage and need for additional capital.
Key Facts
- 79% of verekitug-treated participants achieved clinically meaningful NPS improvement vs 24% placebo (OR 12.06, p<0.0001)
- 72% improved nasal congestion (key secondary endpoint) vs 39% placebo (OR 3.99, p=0.0046)
- 83% improved total symptom score vs 37% placebo (OR 8.57, p<0.0001)
- 69% improved sense of smell vs 21% placebo (OR 8.52, p<0.0001)
- 78% improved Lund-Mackay CT score vs 12% placebo (OR 25.38, p<0.0001)
- 76% reduction in need for surgery or systemic corticosteroids vs placebo (p=0.03)
- Phase 3 initiation planned for Q1 2027 in both CRSwNP and severe asthma
- Verekitug is the only known TSLP receptor antagonist in clinical development
- No serious adverse events observed; favorable safety profile
Financial Impact
No financial data provided; company is pre-revenue clinical-stage biotech with ~$332M market cap
Risk Factors
- Phase 3 trials may fail to replicate Phase 2 results
- Company is pre-revenue and will require substantial additional capital to fund Phase 3 development
- Competition from approved biologics (Tezspire, Dupixent, Nucala, Xolair) in CRSwNP and asthma
- Regulatory interactions on Phase 3 endpoint design are pending and could delay timelines
- COPD Phase 2 trial (VENTURE) is ongoing and results are not yet available
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311448 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 8w ago | 8-K | $6.55 | awaiting T+60 | — | $2.79 (−57.40%) |
Aug 11, 2026 11w ago | 8-K | $7.44 | awaiting T+60 | — | $2.79 (−62.50%) |
Jun 17, 2026 18w ago | Insider Cluster | $6.25 | awaiting T+60 | — | $2.79 (−55.36%) |
Jun 14, 2026 19w ago | Press Release | $6.10 $5.96 | ▼ −2.30% | ▼ −3.30% | $2.79 (−54.26%) |
May 18, 2026 23w ago | Press Release | $8.51 $6.91 | ▼ −18.80% | ▼ −23.65% | $2.79 (−67.22%) |
May 13, 2026 23w ago | Press Release | $9.36 $7.25 | ▲ +22.54% | ▲ +26.98% | $2.79 (+70.19%) |
Apr 17, 2026 27w ago | Press Release | $9.99 $7.14 | ▼ −28.53% | ▼ −34.67% | $2.79 (−72.07%) |
Mar 26, 2026 30w ago | 424B5 | $8.67 $6.41 | ▲ +26.07% | ▲ +42.13% | $2.79 (+67.82%) |
Mar 26, 2026 30w ago | Press Release | $9.79 $6.40 | ▼ −34.68% | ▼ −48.63% | $2.79 (−71.50%) |
Mar 16, 2026 32w ago | Insider Cluster | $9.61 $6.45 | ▼ −32.88% | ▼ −43.37% | $2.79 (−70.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers